Back to top
more

Sangamo Therapeutics (SGMO)

(Delayed Data from NSDQ)

$2.81 USD

2.81
15,302,639

+0.34 (13.77%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $2.82 +0.01 (0.36%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of -13.33% and -31.19%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    Madeleine Johnson headshot

    Bull of the Day: Illumina (ILMN)

    Invest in the medical space with this DNA sequencing-focused company.

      Gilead (GILD) Q2 Earnings & Sales Beat Eclipsed by CEO Exit

      Gilead's GILD) stock is down in after-market trading as the news of departure of the company's CEO has overshadowed the company's second-quarter results, which beat estimates.

        Options Traders Expect Huge Moves in Sangamo Therapeutics (SGMO) Stock

        Sangamo Therapeutics (SGMO) needs investors to pay close attention to the stock based on moves in the options market lately.

          Kevin Cook headshot

          CRISPR Science and Stocks: Knowing Enough to Invest

          Can you learn enough about the science and the companies to invest with confidence?

            Gilead Collaborates with Hookipa for HBV and HIV Therapies

            Gilead Sciences (GILD) collaborates with Hookipa Biotech AG for the development of immunization technologies for HBV and HIV diseases.

              Gilead (GILD) Q1 Earnings & Sales Miss Estimates on Weak HCV

              Gilead (GILD) announced dismal results for the first-quarter as HCV sales plunged further due to increasing competition.

                Has Sangamo Therapeutics (SGMO) Outpaced Other Medical Stocks This Year?

                Is Sangamo Therapeutics, Inc. (SGMO) Outperforming Other Medical Stocks This Year?

                  Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno

                  Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno

                    Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio

                    Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio

                      Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 14.4% in Session

                      Sangamo Therapeutics (SGMO) shares rose more than 14% in the last trading session, amid huge volumes.

                        Kevin Cook headshot

                        Recession is Coming! Not

                        Even if Dalio is only half right, we can bank on the "melt up" and monitor the data like an interest rate hawk

                          Pfizer (PFE) Collaborates With Sangamo for Gene Therapy

                          Pfizer entered into collaboration agreements with Sangamo Therapeutics and private biotech, Arvinas.

                            Arpita Dutt headshot

                            Biotech Stock Roundup: GWPH Submits Epidiolex in the EU, Sangamo Inks Deal with Pfizer

                            Collaboration agreements announced by companies like Sangamo (SGMO) and the submission of a regulatory application for GW's Epidiolex were the key highlights this week in the biotech sector.

                              The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical

                              The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical

                                4 Biotech Stocks Ready to Crush the Market in 2018

                                The biotech sector has performed well in 2017 and we expect the momentum to continue in 2018 driven by new drug approvals. Here, we list stocks which might be worth adding to your biotech portfolio for 2018.

                                  Benjamin Rains headshot

                                  3 Buy-Ranked Biotech Stocks That Soared in 2017

                                  The S&P 500 is up almost 20% in 2017, with the likes of technology giants Nvidia (NVDA) and Amazon (AMZN) helping lift the index to new heights.

                                    Why Sangamo Therapeutics (SGMO) Could Be Positioned for a Surge

                                    Sangamo Therapeutics, Inc. (SGMO) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.

                                      Swarup Gupta headshot

                                      These 5 Stocks Have Popped More Than 100% Since Trump's Win

                                      With tax cuts close to becoming law, it makes sense to pick stocks that have posted stellar performances since Trump's win.

                                        The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics

                                        The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics

                                          Arpita Dutt headshot

                                          5 Top-Ranked Drug Stocks that are Broker Favorites

                                          With the pharma and biotech sector bouncing back in 2017, here is a look at five drug stocks including Sarepta (SRPT) that are broker favorites.

                                            4 Biotech Stocks to Better Your Financial Health This Winter

                                            The biotech industry shows a solid performance so far this year except for a brief slump in between of late. However, it is a good idea to select stocks from a sector that is fundamentally strong.

                                              Is GW Pharma (GWPH) Likely to Beat Earnings Estimates in Q4?

                                              GW Pharma (GWPH) will report its fiscal fourth-quarter results next week. Investors focus is expected to be on commercialization plan for Epidiolex.

                                                Sangamo Therapeutics (SGMO) in Focus: Stock Moves 13.6% Higher

                                                Sangamo Therapeutics (SGMO) shares rose nearly 14% in the last trading session, amid huge volumes.

                                                  Sweta Killa headshot

                                                  Best Sector ETF of Q3 and its Top-Performing Stocks

                                                  Inside the top performing stocks of top U.S.-focused ETF of Q3.